New drug AMT-253 enters human trials for Tough-to-Treat cancers
NCT ID NCT06209580
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial is testing an experimental drug called AMT-253 in about 96 people with advanced melanoma or other solid tumors that have not responded to standard treatments. The study has two parts: first, finding the safest dose, and then expanding to see how well the drug works. The main goals are to check safety and measure tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AMT-253 (an experimental drug given by IV)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced melanoma or other solid tumors that have stopped responding to standard therapies.
What could go wrong
This is a very early, small study (96 people) focused mainly on safety and dosing. The drug may not shrink tumors or could cause serious side effects. Success in early phases does not guarantee later approval.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-••••